06
May
2013
01
May
2013
01
May
2013
Biophyti (France), a clinical stage pharmaceutical company developing a portfolio of nutraceuticals and drug candidates derived from active natural substances to treat metabolic disorders and age related diseases, closed a $2.6M Series B financing. Participants include Metabrain Research, Seventure Partners and CM-CIC Capital Prive.
30
Apr
2013
10
Apr
2013
08
Apr
2013
Posted in I - Series C, Q - 4Q12, R - INTERNATIONAL, X - Device (Cardiology), X - Device (Catheter)
Endosense (Switzerland), a commercial-stage medical device company focused on catheter ablation for cardiac arrhythmias, closed a $40.3M Series C financing. Participants included NGN Capital, Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.
05
Apr
2013
Posted in I - Series C, Q - 4Q12, R - INTERNATIONAL, X - Immunology, X - Inflammation, X - Neurology
TxCell (France), a clinical-stage biotechnology developing cell-based immunotherapies for chronic inflammatory and neurological diseases, closed a $15.9M Series C financing. Participants include CDC Entreprises, Auriga Partners and Seventure Partners. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP [...]
03
Apr
2013
Posted in I - Series E, Q - 4Q12, R - INTERNATIONAL, X - Device (Monitoring)
EarlySense (Israel), a commercial-stage HealthIT company offering a fully integrated patient monitoring and supervision platform, closed a $15M Series E financing. Participants include Pitango Venture Capital, JK&B Captial, ProSeed VC Fund, Docor International Management and Bridge Investment Fund. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds [...]
02
Apr
2013
Posted in I - Series C, Q - 4Q12, R - INTERNATIONAL, X - Device (Ophthalmology)
Sensimed (Switzerland), a commercial-stage medical device company focused on glaucoma-monitoring, closed a $22M Series C financing. Participants include Wellington Partners, Agate Medical Investments, Vinci Capital/Renaissance PME, Sandoz Family Foundation and ELM Development. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive [...]
01
Apr
2013
Posted in I - Series B, Q - 4Q12, R - INTERNATIONAL, X - Antibody, X - Bone Sub, X - Oncology
Alethia Biotherapeutics (Canada), a preclinical-stage biotechnology company focused on bone degredation, closed a $4.7M Series B financing. Participants include AgeChem Venture Fund, BDC Venture Capital and GO Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account [...]
19
Mar
2013
Posted in I - Series C, Q - 4Q12, R - INTERNATIONAL, X - Hepatology
Thrasos Therapeutics (Canada), a clinical-stage pharma company focused on acute kidney injury, closed a $35M Series C financing. Participants include SR One, GSK Canada Life Sciences Innovation Fund, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures. ___________ Collective IP | The Most Comprehensive and Accurate View of [...]
18
Mar
2013
Posted in I - Series B, Q - 4Q12, R - INTERNATIONAL, X - Oncology, X - Parkinson's
Pharma Two B (Israel), a pre-clinical stage pharmaceutical company focused on developing Fixed-Dose-combinations of approved drugs for Parkinson’s disease and Cancer, closed a $8 million Series B financing. Participants include JK&B Capital and Crossroad. ___________ Collective IP the Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem
01
Oct
2012
Posted in I - Series B, Q - 1Q12, R - INTERNATIONAL, X - Hepatology, X - Stem Cell
Promethera Biosciences (Belgium) a clinical stage biotechnology company focused on adult stem cell treatments for liver diseases, closed a $31.4 Series B financing. Participants include Vesalius Biocapital, SRIW, Vives-Louvain Technology Fund, Life Science Research Partners, NivelInvest, Sopartec, Boehringer Ingelheim Ventures, Shire Ventures, Mitsui Global Investment, ATMI and Sambrinvest. Note: Closing out 1Q deals. Thanx for [...]